New research indicates that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who stop traditional diet and exercise programs.
Published data in a prominent medical journal points out that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Users using such drugs need to be informed of the risk of rapid weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass within about one and a half years.
Comparing Therapies
The research, which reviewed dozens of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with other pills.
The team note that individuals who lose weight through lifestyle changes alone typically have a slower creep back—perhaps 100 grams monthly—after stopping.
The Reason for the Rapid Rebound
Doctors propose the mechanism of the jabs is key to understanding the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone concentrations several times higher than normal may cause the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines advise the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, given the likelihood of relapse, the treatment is often long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "emphasize the chronic nature of excess weight," comparing it to managing diseases like diabetes.
User Testimonies
People who have discontinued the jabs explain a sudden resurgence of appetite.
"It felt as if a trigger flipping and I was suddenly extremely hungry," said one woman.
This difficulty is worsened if users have not developed lasting lifestyle or habit changes during treatment.
Widespread Interest
Figures indicate that a significant number of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Use is more common among females than males.
- The middle-aged age group shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on integrated behavioural support.
